Background: Ocular drug delivery is an extremely challenging area due to its restrictive barrier functionalities. Objective: Drug transport via corneal/non-corneal routes involves several intricate biological processes such as drug penetration across the ocular barriers and transfer to the anterior or posterior chambers, thus the influence of these processes on the pharmacotherapy of the eye should be fully addressed. Methods: To pursue the impacts of such impediments in novel drug therapy, recent publications were reviewed regarding advanced strategies such as nanomedicines. Conclusion: The ocular barriers are highly specialized and selectively control the inward/outward traverse of compounds, hence a better understanding of these biological obstacles would provide a platform to advance ophthalmic drug therapy towards specified delivery/targeting with minimal adverse consequences.

Doxorubicin Changes Bax /Bcl-xL Ratio, Caspase-8 and 9 in Breast Cancer Cells

A gold electrode decorated with gold nanoparticles, CdSe quantum dots and anti-CA-125 antibody (MPA|AuNP@SiO ₂ |QD|mAb immunosensor) sensitively specifically detects the CA-125 oncomarker.